143 results on '"Patricia, de Cremoux"'
Search Results
2. Sélection et décryptage - L’innovation en cancérologie à travers la presse scientifique et médicale
- Author
-
Patricia de Cremoux and Jacques Robert
- Published
- 2022
3. Supplementary Materials and Methods from Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
- Author
-
Elisabetta Marangoni, Didier Decaudin, Ivan Bièche, Patricia de Cremoux, Samantha Goodstal, Edward Spooner, Xiaohong Liu, Jean-Jacques Fontaine, Jean-Luc Servely, Marie-France Poupon, Sophie Chateau-Joubert, Franck Assayag, Anderson Clark, and Angela Romanelli
- Abstract
PDF file - 108 KB, This file provides additional details on methods and protocols.
- Published
- 2023
4. Data from Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
- Author
-
Elisabetta Marangoni, Didier Decaudin, Ivan Bièche, Patricia de Cremoux, Samantha Goodstal, Edward Spooner, Xiaohong Liu, Jean-Jacques Fontaine, Jean-Luc Servely, Marie-France Poupon, Sophie Chateau-Joubert, Franck Assayag, Anderson Clark, and Angela Romanelli
- Abstract
Triple-negative breast cancers (TNBC) have an aggressive phenotype with a relatively high rate of recurrence and poor overall survival. To date, there is no approved targeted therapy for TNBCs. Aurora kinases act as regulators of mammalian cell division. They are important for cell-cycle progression and are frequently overexpressed or mutated in human tumors, including breast cancer. In this study, we investigated the therapeutic potential of targeting Aurora kinases in preclinical models of human breast cancers using a pan-inhibitor of Aurora kinases, AS703569. In vitro, AS703569 was tested in 15 human breast cancer cell lines. TNBC cell lines were more sensitive to AS703569 than were other types of breast cancer cells. Inhibition of proliferation was associated with cell-cycle arrest, aneuploidy, and apoptosis. In vivo, AS703569 administered alone significantly inhibited tumor growth in seven of 11 patient-derived breast cancer xenografts. Treatment with AS703569 was associated with a decrease of phospho-histone H3 expression. Finally, AS703569 combined to doxorubicin–cyclophosphamide significantly inhibited in vivo tumor recurrence, suggesting that Aurora kinase inhibitors could be used both in monotherapy and in combination settings. In conclusion, these data indicate that targeting Aurora kinases could represent a new effective approach for TNBC treatment. Mol Cancer Ther; 11(12); 2693–703. ©2012 AACR.
- Published
- 2023
5. Supplementary Figure Legend from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 108K
- Published
- 2023
6. Supplementary Data 3 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 317K, List of EMT- and autophagy-related differentially expressed genes in SNAI1- and SNAI1-6SA-expressing MCF-7 cells
- Published
- 2023
7. Supplementary Data 1 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 204K, Cancer stem cell properties of EMTed and autophagic cell lines
- Published
- 2023
8. Supplementary Data 5 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 10396K, Human breast cancer biopsies were stained for SNAI2 and LC3B expression by immunohistochemistry on serial tumor sections
- Published
- 2023
9. Supplementary Data 2 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 72K, SNAI1-6SA cells were sorted by flow cytometry (MoFlo� Astrios� - Beckman Coulter, Inc) based on their ALDH activity
- Published
- 2023
10. Supplementary Data 4 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
- Author
-
Salem Chouaib, Fathia Mami-Chouaib, Jean Paul Thiery, Nicole Tsang Ying Hung, Joan Herr Keira, Tuan Zea Tan, Michèle Sabbah, Annette K. Larsen, Philippe Vielh, Cécile Badoual, Philippe Bertheau, Patricia De Cremoux, Fabrice André, Muhammad Zaeem Noman, Meriem Hasmim, Bassam Janji, and Intissar Akalay
- Abstract
PDF file - 160K, Data mining of microarray data showing the connections between EMT and autophagy-related genes
- Published
- 2023
11. Abstract P1-07-06: Endoxifen exposure after 5 weeks of preoperative tamoxifen is predictive of long-term outcome of operable hormone receptor positive (HR+) HER2 - early breast cancer
- Author
-
Jean-Sebastien Frenel, Loic Campion, Antonin Schmitt, Patricia De Cremoux, Elsa Rossignol, Celine Renaudeau, Marie Robert, Jean-Marie Bard, Christine Bobin-Dubigeon, and Mario Campone
- Subjects
Cancer Research ,Oncology ,skin and connective tissue diseases - Abstract
Introduction: Endoxifen exposure, the most active metabolite of tamoxifen, may be a better predictor of tamoxifen efficacy, than CYP2D6 genotypes. However, conflicting results have been reported so far. We evaluated prospectively the impact of 5 weeks of pre-operative tamoxifen on Ki-67 levels in early-stage breast cancer (EBC) patients. We correlated CYP2D6 genotype, exposure of tamoxifen and its metabolites with long-term outcome. Patients and methods: TAM pre-op was an open-label, multicentre, phase 2 trial in which pre and postmenopausal women with WHO performance status 0-1 and HR+ HER2-, operable breast cancer were given tamoxifen (20mg per day orally) for 5 weeks before surgery. Adjuvant treatments were given as standard practice. CYP2D6 genotype was determined at initiation. Plasma concentrations of tamoxifen and its main metabolites (N-desmethyltamoxifen, Z-endoxifen, and Z-4-hydroxytamoxifen) were assessed at baseline (b), week 2 (w2) and week 5 (w5) of treatment, using a validated performed LC-MS/MS method. AUCs, used as marker of exposure, were computed with Monolix© (Lixoft, Antony, France). Tumour Ki-67 variations between baseline (Ki-67b) and w5 (Ki-67w5) were determined to assess the sensitivity to tamoxifen. We used a pre-defined 10% cut-off to dichotomize low versus high Ki-67. All these parameters were associated with disease free survival by Cox regression analyses. Results: Out of the 136 patients enrolled, 98 pts had paired Ki-67 values evaluable. With a median follow up of 78 months (IQR 58-95), 14/136 women had cancer recurrence (12 distant and 2 contralateral) with the proportion free from cancer recurrence at 5 years of 90% (95% CI 83-94). Ki-67b, Ki-67w5 and variations between baseline and week 5 were not associated with DFS. Endoxifen AUC was correlated with CYP2D6 genotype (normal/hyper metabolizer versus low metabolizer) but CYP2D6 genotype was not predictive for DFS (adjusted hazard ratio, 2.24; 95% CI, 0.29 to 17.37; P = 0.44). Endoxifen AUCs at w2 and w5 were similar in patients with low Ki67b and low Ki67w5 (low-low) (n=36), low Ki67b and high Ki67w5 (n=12), high Ki67b and low Ki67w5 (n=14) and high Ki67b and high Ki67w5 (n=30). However, low endoxifen AUC at w5 was a pejorative factor of disease free survival: 5 years PFS 81.8% vs 90.3% (HR 2.70, CI 95% [1.04-7.06], p=0.04). Conclusion: This prospective clinical study shows that endoxifen exposure at w5 of pre-operative tamoxifen is associated with DFS in patients with HR+/HER2- EBC. Translationnal studies are ongoing. N°EUDRACT 2008-007652-10. Citation Format: Jean-Sebastien Frenel, Loic Campion, Antonin Schmitt, Patricia De Cremoux, Elsa Rossignol, Celine Renaudeau, Marie Robert, Jean-Marie Bard, Christine Bobin-Dubigeon, Mario Campone. Endoxifen exposure after 5 weeks of preoperative tamoxifen is predictive of long-term outcome of operable hormone receptor positive (HR+) HER2 - early breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-07-06.
- Published
- 2022
12. Monitoring Breast Cancer Care Quality at National and Local Level Using the French National Cancer Cohort
- Author
-
Sophie Houzard, Emilie Courtois, Christine Le Bihan Benjamin, Marie Erbault, Laurent Arnould, Emmanuel Barranger, Florence Coussy, Benoît Couturaud, Bruno Cutuli, Patricia de Cremoux, Pia de Reilhac, Chantal de Seze, Aude-Marie Foucaut, Anne Gompel, Stéphane Honoré, Anne Lesur, Carole Mathelin, Laurent Verzaux, and Philippe-Jean Bousquet
- Subjects
Cancer Research ,Oncology ,Humans ,Breast Neoplasms ,Female ,Radiotherapy, Adjuvant ,Mastectomy, Segmental ,Quality Indicators, Health Care ,Quality of Health Care - Abstract
The French National Cancer Institute has developed, in partnership with the French National Authority for Health, breast cancer-specific Care Quality, and Safety Indicators (BC QIs). With regard to the most common form of cancer, our aim is to support local and national quality initiatives, to improve BC pathways and outcomes, reduce heterogeneity of practice and regional inequities. In this study, we measure the BC QIs available in the French National medico-administrative cancer database, the French Cancer Cohort, for 2018.BC QIs are developed according to the RAND method. QIs are based on good clinical practice and care pathway recommendations. QI computation should be automatable without any additional workload for data collection. They will be published annually for all stakeholders, and especially hospitals.Finally, ten feasible and pertinent QIs were selected. In France, BC care was found to be close to compliance with most QIs: proportion of patients undergoing biopsy prior to first treatment (94.5%), proportion of patients undergoing adjuvant radiotherapy after breast-conserving surgery for BC (94.5%), proportion of women undergoing radiotherapy within 12 weeks after surgery and without chemotherapy (86.2%), proportion of DCIS patients undergoing immediate breast reconstruction (54.3%) and proportion of women with NMIBC undergoing breast reintervention (14.4%). However, some are still far from their recommended rate. In particular, some QIs vary considerably from one region, or one patient, to another.Each result needs to be analyzed locally to find care quality leverage. This will strengthen transparency actions aimed at the public.
- Published
- 2022
13. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
- Author
-
Aymeric Amelot, Patricia De Cremoux, Véronique Quillien, Marc Polivka, Homa Adle-Biassette, Jacqueline Lehmann-Che, Laurence Françoise, Antoine F Carpentier, Bernard George, Emmanuel Mandonnet, and Sébastien Froelich
- Subjects
Medicine ,Science - Abstract
A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS) are found among those IDH1/2 mutated patients.We retrospectively analyzed 207 GBM patients followed at Lariboisière Hospital (Paris) between 2005 and 2010. Clinical parameters were obtained from medical records. Mutations of IDH1/2 were analyzed in these patients, by immunohistochemistry for the R132H mutation of IDH1 and by high-resolution melting-curve analysis, followed by Sanger sequencing for IDH1 and IDH2 exon 4 mutations. Mutation rates in LTS and non-LTS groups were compared by Chi square Pearson test.Seventeen patients with survival >3 years were identified (8.2% of the total series). The median overall survival in long-term survivors was 4.6 years. Subgroup analysis found that the median age at diagnosis was significantly higher for non long-term survivors (non-LTS) compared to LTS (60 versus 51 years, p
- Published
- 2015
- Full Text
- View/download PDF
14. Concomitant Bifocal Urothelial Carcinoma and Breast Tumor: Second Primary Cancer or Metastatic Spread to the Breast?
- Author
-
Clément Dumont, Hélène Gauthier, Jérôme Vérine, Jacqueline Lehmann-Che, Patricia de Cremoux, Damien Pouessel, and Stéphane Culine
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Metastases to the mammary gland are an uncommon event in the natural history of most malignant tumors. We report the case of a 60-year-old woman who presented initially with bifocal urothelial carcinoma with a single breast tumor, raising the issue of a primary cancer or a metastatic spread to the breast. The diagnosis of breast metastasis was aided by identity of pathology, immunochemistry, and molecular biology findings between the primary tumor and the breast lesion, among which are the p.K120M mutation, a very rare TP53 mutation, and HER2 overexpression with underlying polysomy of chromosome 17.
- Published
- 2014
- Full Text
- View/download PDF
15. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.
- Author
-
Hélène Blons, Etienne Rouleau, Nathanaël Charrier, Gilles Chatellier, Jean-François Côté, Jean-Christophe Pages, Florence de Fraipont, Jean-Christophe Boyer, Jean Philippe Merlio, Alain Morel, Marie-Claude Gorisse, Patricia de Cremoux, Karen Leroy, Gérard Milano, L'houcine Ouafik, Jean-Louis Merlin, Delphine Le Corre, Pascaline Aucouturier, Jean-Christophe Sabourin, Frédérique Nowak, Thierry Frebourg, Jean-François Emile, Isabelle Durand-Zaleski, Pierre Laurent-Puig, and MOKAECM Collaborative Group
- Subjects
Medicine ,Science - Abstract
Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in colorectal cancer, and anti-EGFR antibodies use was limited to KRAS wild type tumors. In order to ensure wide access to tumor molecular profiling, the French National Cancer Institute (INCa) has set up a national network of 28 regional molecular genetics centers. Concurrently, a nationwide external quality assessment for KRAS testing (MOKAECM) was granted to analyze reproducibility and costs.96 cell-line DNAs and 24 DNA samples from paraffin embedded tumor tissues were sent to 40 French laboratories. A total of 5448 KRAS results were collected and analyzed and a micro-costing study was performed on sites for 5 common methods by an independent team of health economists.This work provided a baseline picture of the accuracy and reliability of KRAS analysis in routine testing conditions at a nationwide level. Inter-laboratory Kappa values were >0.8 for KRAS results despite differences detection methods and the use of in-house technologies. Specificity was excellent with only one false positive in 1128 FFPE data, and sensitivity was higher for targeted techniques as compared to Sanger sequencing based methods that were dependent upon local expertise. Estimated reagent costs per patient ranged from €5.5 to €19.0.The INCa has set-up a network of public laboratories dedicated to molecular oncology tests. Our results showed almost perfect agreements in KRAS testing at a nationwide level despite different testing methods ensuring a cost-effective equal access to personalized colorectal cancer treatment.
- Published
- 2013
- Full Text
- View/download PDF
16. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy
- Author
-
Magali Lacroix-Triki, Clara Nahmias, Jean-Yves Pierga, Elisabetta Marangoni, Marie-Eglantine Dujaric, Patricia de Cremoux, Nicolas Servant, Bernard Asselain, Fabrice Andre, Cynthia Seiler, Monica Arnedos, Sylvie Rodrigues-Ferreira, Clarisse Monchecourt, Sophie Chateau-Joubert, Hadia Moindjie, Anne Nehlig, Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse (U981), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Excellence en Recherche sur le Médicament et l'Innovation Thérapeutique [Châtenay-Malabry] (LabEx LERMIT), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Gustave Roussy (IGR), Institut Curie [Paris], Université Paris sciences et lettres (PSL), BioPôle Alfort, École nationale vétérinaire d'Alfort (ENVA), MINES ParisTech - École nationale supérieure des mines de Paris, Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de biologie et pathologie médicales [Gustave Roussy], Département de médecine oncologique [Gustave Roussy], Université Paris Descartes - Paris 5 (UPD5), Université Sorbonne Paris Cité (USPC), Hôpital René HUGUENIN (Saint-Cloud), École nationale vétérinaire - Alfort (ENVA), Mines Paris - PSL (École nationale supérieure des mines de Paris), and NAHMIAS, Clara
- Subjects
0301 basic medicine ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Aneuploidy ,Video microscopy ,[SDV.BC.BC]Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC] ,Microtubules ,chemistry.chemical_compound ,0302 clinical medicine ,Multicenter Studies as Topic ,ATIP3 ,predictive biomarker ,Randomized Controlled Trials as Topic ,education.field_of_study ,Multidisciplinary ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,DNA, Neoplasm ,Biological Sciences ,Neoadjuvant Therapy ,3. Good health ,Neoplasm Proteins ,[SDV] Life Sciences [q-bio] ,MTUS1 ,Paclitaxel ,030220 oncology & carcinogenesis ,Heterografts ,RNA Interference ,Taxoids ,Population ,Breast Neoplasms ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Spindle Apparatus ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Time-Lapse Imaging ,03 medical and health sciences ,Breast cancer ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Cell Line, Tumor ,medicine ,[SDV.BC.BC] Life Sciences [q-bio]/Cellular Biology/Subcellular Processes [q-bio.SC] ,Humans ,Neoplasm Invasiveness ,education ,Mitosis ,[SDV.BC] Life Sciences [q-bio]/Cellular Biology ,Cytokinesis ,multipolar spindle ,Chemotherapy ,business.industry ,Gene Expression Profiling ,Tumor Suppressor Proteins ,medicine.disease ,Antineoplastic Agents, Phytogenic ,030104 developmental biology ,chemistry ,Drug Resistance, Neoplasm ,taxanes ,Cancer research ,business ,Multipolar spindles ,Neoplasm Transplantation ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Predictive biomarkers for tumor response to neoadjuvant chemotherapy are needed in breast cancer. This study investigates the predictive value of 280 genes encoding proteins that regulate microtubule assembly and function. By analyzing 3 independent multicenter randomized cohorts of breast cancer patients, we identified 17 genes that are differentially regulated in tumors achieving pathological complete response (pCR) to neoadjuvant chemotherapy. We focused on the MTUS1 gene, whose major product, ATIP3, is a microtubule-associated protein down-regulated in aggressive breast tumors. We show here that low levels of ATIP3 are associated with an increased pCR rate, pointing to ATIP3 as a predictive biomarker of breast tumor chemosensitivity. Using preclinical models of patient-derived xenografts and 3-dimensional models of breast cancer cell lines, we show that low ATIP3 levels sensitize tumors to the effects of taxanes but not DNA-damaging agents. ATIP3 silencing improves the proapoptotic effects of paclitaxel and induces mitotic abnormalities, including centrosome amplification and multipolar spindle formation, which results in chromosome missegregation leading to aneuploidy. As shown by time-lapse video microscopy, ATIP3 depletion exacerbates cytokinesis failure and mitotic death induced by low doses of paclitaxel. Our results favor a mechanism by which the combination of ATIP3 deficiency and paclitaxel treatment induces excessive aneuploidy, which in turn results in elevated cell death. Together, these studies highlight ATIP3 as an important regulator of mitotic integrity and a useful predictive biomarker for a population of chemoresistant breast cancer patients.
- Published
- 2019
17. 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients
- Author
-
Philippe Bertheau, Lucie Biard, Brigitte Poirot, Christos Sotiriou, Luis Augusto Teixeira, Jacqueline Lehmann-Che, Matthieu Resche-Rigon, Patricia de Cremoux, Pascal Merlet, Fatiha Bouhidel, David Groheux, and Marc Espié
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,18FDG-PET/CT ,Neoadjuvant chemotherapy ,03 medical and health sciences ,Breast cancer ,0302 clinical medicine ,breast cancer ,Internal medicine ,Biopsy ,medicine ,TP53 status ,Chemotherapy ,Pathological complete response ,medicine.diagnostic_test ,business.industry ,Surrogate endpoint ,HER2 negative ,medicine.disease ,3. Good health ,030104 developmental biology ,Real-time polymerase chain reaction ,Positron emission tomography ,030220 oncology & carcinogenesis ,pathological complete response ,Fdg pet ct ,business ,Psychiatrie ,Research Paper ,neoadjuvant chemotherapy - Abstract
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients. Methods: We used metabolic PET parameters, at diagnosis and after two cycles of chemotherapy and proliferation gene expression profile on biopsy at diagnosis, in particular, the genomic grade index (GGI) analyzed by reverse transcription and quantitative polymerase chain reaction (RT-qPCR). The pathological response was the surrogate endpoint. Results: The change of FDG uptake between baseline PET and interim PET after 2 cycles of neoadjuvant chemotherapy (ΔSUVmax) was highly associated with pCR (p=0.008). We also observed an ability of P53 mutated status (p=0.042), in addition to histological grade (p=0. 0004), and PR expression (p=0.01) to predict pCR in ERpositive BCs, whereas no proliferation marker predicted pCR (P=0.39 for GGI). Finally, only ΔSUVmax was significantly associated with event free survival (p=0.047). Conclusions: Our results confirm the predictive and prognostic value of tumor ΔSUVmax in ER-positive /HER2-negative advanced BCs patients. These findings can be helpful to select high-risk patients within trials investigating novel treatment strategies., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
18. Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution Study
- Author
-
Anne De La Rochefordiere, Youlia Kirova, Severine Alran, Corine Plancher, Virginie Fourchotte, Philippe Beuzeboc, Vincent De Margerie, Peter Petrow, Xavier Sastre-Garau, Vincent Servois, Suzy Scholl, Paul Cottu, Laurent Mignot, Patricia De Cremoux, and Remy Salmon
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective To evaluate the treatment results of patients (pts) with FIGO stage IB2, IIA, IIB cervical carcinoma (CC) treated with pre-operative radio-chemotherapy, followed by extended radical hysterectomy. Methods Retrospective study of 148 women treated to the Institut Curie for operable FIGO Stage IB2 to IIB, biopsy proved CC. Among them, 70 pts, median age 46 years, were treated using the same regimen associating primary radio-cisplatinum based chemotherapy, intracavitary LDR brachytherapy, followed by extended radical hysterectomy. Kaplan-Meier estimates were used to draw survival curves. Comparisons of survival distribution were assessed by the log-rank test. Results Complete histological local-regional response was obtained in 56% of the pts (n = 39). Residual macroscopic or microscopic disease in the cervix was observed in 28 pts (40%). All but one had in-situ microscopic residual CC. Lateral residual disease in the parametria was also present in 9 pts, all with residual CC. Pelvic lymph nodes were free from microscopic disease in 56 pts (80%). Eight of 55 (11%) radiological N0 patients had microscopic nodal involvement, as compared to 6/15 (40%) radiological N1 (p = 0.03). Seventeen pts (25%) had residual cervix disease but negative nodes. After median follow-up of 40 months (range, 8–141), 38/70 patients (54.1%) are still alive and free of disease, 6 (8.6%) alive with disease, and 11 (15.8%) patients were lost for follow-up but free of disease. In Conclusion The treatment of locally advanced CC needs a new multidisciplinary diagnostic and treatment approach using new therapeutic arms to improve the survival and treatment tolerance among women presenting this disease.
- Published
- 2008
- Full Text
- View/download PDF
19. Massive open online course (MOOC) sur le diagnostic des cancers : bilan et évaluation de l’impact sur la perception de l’anatomie et cytologie pathologiques
- Author
-
Maxime Battistella, Cédric de Bazelaire, Yohann Pottier, Jeanne Tran Van Nhieu, Jocelyne Gervais, Emilie Moenaert, Patricia de Cremoux, Thierry Jo Molina, Laurent Prévaut, Karima Sekri, Julien Calvani, Marie Sockeel, Charlotte Gardair, Guilhem Bousquet, Philippe Bertheau, Jaqueline Lehmann-Che, and Michel Peuchmaur
- Subjects
03 medical and health sciences ,Medical education ,0302 clinical medicine ,020205 medical informatics ,Massive open online course ,0202 electrical engineering, electronic engineering, information engineering ,Teaching program ,030212 general & internal medicine ,02 engineering and technology ,Pathology and Forensic Medicine - Abstract
The Massive Open Online Course (or MOOC) "Diagnostic Strategies Cancers", was hosted in autumn 2016 on the platform "France Universite Numerique" and had two levels of learners: students in the field of health and biology and the general public. Of the 5285 learners in 81 different countries, 1237 (23%) were successfully certified. This MOOC was also integrated into the teaching program of medical students of Paris Diderot University and Paris 13 University. Using anonymous questionnaires before and after MOOC, it has been shown that pathology is less known than other medical specialties. Participation in this MOOC led to a marked improvement in participants' knowledge of the place and role of the pathologist in the diagnosis of cancers. Regarding the students who have followed the MOOC as part of their university course, their comments were very positive, but it is necessary to make substantial adjustments in the amounts and contents of the campus-based courses.
- Published
- 2017
20. Un cas de gliome chordoïde inhabituel : aspects immunohistochimiques et moléculaires et diagnostics différentiels
- Author
-
Gilles Robert, Arnault Tauziède-Espariat, Marc Polivka, and Patricia de Cremoux
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Brachyury ,business.industry ,CD34 ,Optic chiasm ,Histogenesis ,medicine.disease ,Pathology and Forensic Medicine ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Glioma ,medicine ,Atypia ,Immunohistochemistry ,business ,Epithelioid cell ,030217 neurology & neurosurgery - Abstract
We report the case of a 63-year-old healthy patient who was admitted for surgery of a suprasellar tumor with extension to the optic chiasm responsible of visual disturbance. Histopathological examination revealed a tumoral proliferation composed of epithelioid cells without atypia arranged in cords in a mucinous matrix surrounded by some lymphocytic inflammatory infiltrates. On immunohistochemistry, the neoplastic cells strongly expressed GFAP and CD34, a weak expression of EMA, an expression of TTF1 without immunoreactivity for brachyury. Ki-67 labeling index was low around 1%. The diagnosis of chordoid glioma was made. Surprisingly, tumor cells expressed IDH1R132H but molecular analysis did not reveal any mutation of IDH1/2 genes. There was no expression of p53 but high overexpression of EGFR. Chordoid glioma is a rare and low-grade entity. The precise histogenesis remains debated. Our case is unusual because of the infiltration of the optic chiasm and because of the immunoexpression of IDH1R132H without underlying mutations of IDH1/2 genes.
- Published
- 2017
21. Les coulisses d’un Massive Open Online Course (MOOC) sur le diagnostic des cancers
- Author
-
Jacqueline Lehmann-Che, Karima Sekri, Maxime Battistella, Cédric de Bazelaire, Julien Calvani, Laurent Prévaut, Jocelyne Gervais, Philippe Bertheau, Charlotte Gardair, Yohann Pottier, Guilhem Bousquet, Marie Sockeel, Patricia de Cremoux, and Jeanne Tran Van Nhieu
- Subjects
03 medical and health sciences ,0302 clinical medicine ,020205 medical informatics ,030220 oncology & carcinogenesis ,media_common.quotation_subject ,0202 electrical engineering, electronic engineering, information engineering ,02 engineering and technology ,Art ,Humanities ,Pathology and Forensic Medicine ,media_common - Abstract
Resume Le cours en ligne ouvert et massif (Massive Open Online Course ou MOOC) est une nouvelle modalite pedagogique en ligne s’adressant a une audience dont la taille est sans precedent par rapport aux autres strategies d’enseignement tout en permettant des interactions avec une equipe pedagogique. Ces cours universitaires, le plus souvent encore gratuits, donnent lieu a la remise d’une attestation de suivi et pourraient rapidement etre diplomants. Le MOOC « Strategies diagnostiques des cancers » sera dispense a l’automne 2016 sur la plateforme France universite numerique et aura deux niveaux d’apprenants : les etudiants de premier cycle dans le domaine de la sante et de la biologie et le grand public. Il sera egalement integre a des unites d’enseignement pour des etudiants en medecine des universites Paris Diderot et Paris 13. L’objectif pedagogique de ce MOOC est de transmettre a l’ensemble des apprenants une vision globale des etapes diagnostiques du cancer et des differentes specialites medicales impliquees dans ce diagnostic. La deuxieme semaine d’enseignement de ce MOOC, intitulee « le prelevement tumoral, son analyse macroscopique et microscopique », presente la specialite d’anatomie et cytologie pathologiques avec la prise en charge technique des echantillons tissulaires ou cellulaires et les elements basiques du raisonnement anatomopathologique. A l’issue de ce MOOC, il est prevu de realiser une evaluation de l’impact de cette nouvelle modalite d’enseignement sur la perception de l’anatomie et cytologie pathologiques par le grand public.
- Published
- 2016
22. Le Conseil national des universités en cancérologie-radiothérapie : missions et critères de sélection présentés aux lecteurs du Bulletin du Cancer
- Author
-
Marc Espié, Lina Bolotine, Jean-Charles Soria, Anne Laprie, Lucie Karayan-Tapon, Jocelyn Céraline, Henri Roché, Patricia de Cremoux, Jean-Jacques Mazeron, Sylvie Negrier, Gilles Calais, and Gérard Bastian
- Subjects
0301 basic medicine ,03 medical and health sciences ,Cancer Research ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Political science ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine - Published
- 2016
23. Diagnostic du carcinome canalaire in situ : 3 recommandations nationales françaises
- Author
-
Marie-Pierre Chauvet, Luc Ceugnart, A. Lesur, Stéphanie Besnard, Christophe Hennequin, Bruno Cutuli, Alain Fourquet, Antoine Arnaud, Patricia de Cremoux, Audrey Lesieur, Philippe Bertheau, Christine Tunon de Lara, Charles Coutant, Véronique Boute, Chantal Belorgey, Anne Vincent-Salomon, Laurent Lévy, and L. Boulanger
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,Low-Grade DCIS ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,medicine ,Ductal carcinoma ,business ,030218 nuclear medicine & medical imaging ,Pathology and Forensic Medicine - Abstract
Resume Objectif Depuis les dernieres recommandations nationales elaborees par l’Institut national du cancer (INCa) et la Societe francaise de senologie et de pathologie mammaire (SFSPM) sur l’ensemble de la prise en charge diagnostique et therapeutique des carcinomes canalaires in situ (CCIS), de nouvelles publications ont fait emerger des interrogations en termes de bonnes pratiques et sur les possibilites de desescalade therapeutique dans la prise en charge des CCIS. L’actualisation de ces recommandations intervient dans un contexte de questionnement sur le surdiagnostic et son corollaire le surtraitement. Elle met a la disposition des professionnels des informations sur les bonnes pratiques correspondant a l’etat le plus recent des connaissances scientifiques et etudie notamment les possibilites de desescalade therapeutique. Methode Le processus d’elaboration est base sur une revue systematique de la litterature et sur le jugement argumente d’experts cliniciens au sein d’un groupe de travail multidisciplinaire. Avant publication, les recommandations sont revues par plus de cent experts cliniciens independants du groupe de travail. Resultats Cet article presente les recommandations nationales relatives a l’indication de l’IRM, la place de la macrobiopsie en cas de microcalcifications et la conduite a tenir en cas de CCIS de bas grade identifie par biopsie, dans le diagnostic des CCIS.
- Published
- 2016
24. 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen
- Author
-
Luis Augusto Teixeira, Sylvie Giacchetti, Lucie Biard, Laetitia Vercellino, Anne de Roquancourt, Patricia de Cremoux, Pascal Merlet, David Groheux, Caroline Cuvier, Elif Hindié, Matthieu Resche-Rigon, and Marc Espié
- Subjects
Oncology ,Chemotherapy ,medicine.medical_specialty ,Dose-dense chemotherapy ,Anthracycline ,business.industry ,medicine.medical_treatment ,medicine.disease ,Chemotherapy regimen ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Regimen ,0302 clinical medicine ,Breast cancer ,Docetaxel ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,business ,medicine.drug ,Epirubicin - Abstract
Patients with triple-negative breast cancer (TNBC) have poor outcome when pathologic complete response (pCR) is not reached after neoadjuvant chemotherapy. Early prediction would be helpful. We evaluated the association between metabolic response after 2 cycles of neoadjuvant chemotherapy, pCR, and outcome in patients receiving 2 different anthracycline-based regimens (conventional and intensified). Methods: Of 77 consecutive TNBC patients, 23 received EC-D (4 cycles of epirubicin + cyclophosphamide followed by 4 cycles of docetaxel at conventional doses) and 55 received a dose-intensified, dose-dense concomitant regimen of epirubicin + cyclophosphamide (historically called SIM) for 6 cycles. PET/CT with 18F-FDG was performed at baseline and after 2 cycles of neoadjuvant chemotherapy. The associations between clinical factors, biologic factors, early metabolic change, pCR, and event-free survival (EFS) were examined (log-rank test). Results: Of the 78 patients, 29 (37%) achieved pCR. The change in SUVmax (∆SUVmax) after 2 cycles was more pronounced in patients who achieved pCR (−72% vs. −42%; P
- Published
- 2015
25. COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients
- Author
-
Sylvie Giacchetti, Jacqueline Lehmann-Che, Ivan Bièche, Jean Marc Guinebretière, Philippe Bertheau, Bernard Asselain, Frédérique Spyratos, Patricia de Cremoux, Marie-Christine Mathieu, Jean-Yves Pierga, Véronique Scott, Michel Marty, Anne-Sophie Hamy, B Sigal, and Etienne Brain
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,macromolecular substances ,03 medical and health sciences ,Breast cancer ,Internal medicine ,Progesterone receptor ,Gene expression ,medicine ,skin and connective tissue diseases ,Prospective cohort study ,Neoadjuvant therapy ,030102 biochemistry & molecular biology ,business.industry ,food and beverages ,General Medicine ,medicine.disease ,Real-time polymerase chain reaction ,Predictive value of tests ,Celecoxib ,business ,medicine.drug - Abstract
BACKGROUND The prognostic and predictive role of cyclo-oxygenase-2 (COX2) in breast cancer is still debated, and in particular, its role as a target of COX2 inhibitor (celecoxib) in neoadjuvant setting. MATERIALS AND METHODS We analyzed a series of 156 breast cancer samples from patients of the COX2 inhibitor-treated arm included in the REMAGUS-02 randomized phase II trial. COX2 gene expression was assessed by reverse transcription and quantitative polymerase chain reaction using ribonucleic acid from frozen biopsies. Pathological complete response (pCR) was the surrogate end-point. RESULTS Significantly higher rates of grade 3, and estrogen and progesterone receptor negativity were observed in tumors with the highest expression of COX2. pCR rates were significantly higher in COX2-overexpressing tumors in patients receiving celecoxib. The test for interaction between COX2 gene expression and the celecoxib effect was statistically significant (p
- Published
- 2018
26. [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management]
- Author
-
Pierre-Jean Lamy, Anne-Gaëlle Le Corroller, Diana Kassab-Chahmi, Laetitia Verdoni, Julia Bonastre, Elisabeth Luporsi, Valérie Mazeau-Woynar, Frédéric Fina, Chafika Mazouni, Patricia de Cremoux, Jérôme Barrière, J. P. Peyrat, Jean-Pierre Bellocq, Pierre-Marie Martin, Gilles Romieu, Jérôme Chetritt, Anne-Sophie Gauchez, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Service d'Anatomie Pathologique Générale [CHU Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut Gustave Roussy (IGR), Institut d'Histopathologie [Nantes], Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Plateforme de radioactivité [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Biologie et de Pathologie [CHU Grenoble] (IBP), UNICANCER - Institut régional du Cancer Montpellier Val d'Aurelle (ICM), CRLCC Val d'Aurelle - Paul Lamarque, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Institut National du Cancer [Boulogne Billancourt] (INC), L'Institut national du cancer a reçu le soutien financier d'Unicancer pour la conduite de ce projet., Université Côte d'Azur (UCA)-UNICANCER, Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Biologie et de Pathologie - IBP [CHU Grenoble]-Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), Université Lille Nord de France (COMUE)-UNICANCER, and Dupuis, Christine
- Subjects
Cancer Research ,Predictive value ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Pathology and Forensic Medicine ,03 medical and health sciences ,Breast cancer ,0302 clinical medicine ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Medicine ,Radiology, Nuclear Medicine and imaging ,skin and connective tissue diseases ,Cancer du sein ,Niveaux de preuve ,030304 developmental biology ,Biomarqueurs ,0303 health sciences ,business.industry ,Valeur pronostique ,Hematology ,General Medicine ,Prognosis ,Valeur prédictive ,3. Good health ,Levels of evidence ,Oncology ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,business ,Biomarkers - Abstract
CONTEXT AND AIMS:Breast cancer prognosis and predictive biomarkers development would allow sparing some patients from chemotherapy or identifying patients for whom chemotherapy would be indicated. In this context, in 2009, the French National Cancer Institute, a National Health and Science Agency dedicated to cancer, in collaboration with the French society of senology and breast pathology (SFSPM) published a report on the assessment of the prognostic and the predictive clinical validity of tissular biomarkers, uPA/PAI-1, Oncotype DX™ and MammaPrint(®), in breast cancer management. They concluded that only the uPA/PAI-1 prognosis value reached the highest level of evidence (LOE I according to Hayes 1998 classification). In 2012, it was decided to update this report since new data have emerged and because information disparities among clinicians have been identified. This article aims to present the main conclusions together with the levels of evidence associated with those conclusions.METHODS:The updating process was based on literature published since 2009 appraisal and on multidisciplinary and independent experts' opinion. The levels of evidence (LOE) used are those of the classification defined by Simon in 2009 (updated Hayes 1998 classification): LOE IA and LOE IB: high level of evidence; LOE IIB and LOE IIC: intermediate level of evidence; LOE IIIC and LOE IV-VD: low level of evidence.CONCLUSIONS:Among patients without lymph-node involvement, uPA/PAI-1, invasion process biomarkers, reach the highest level of evidence for 10 years recurrence free survival prognosis (LOE IA according to Simon). The predictive value to anthracyclins chemotherapy remains to be confirmed. Oncotype DX™ and MammaPrint(®) prognosis and predictive value do not reach the LOE I level. This updating' process confirms the 2009 levels of evidence for all the three biomarkers prognosis value. Besides, concerning Oncotype DX™ and MammaPrint(®), new data do not allow to conclude neither to their complementary clinical information to other clinicopathological existing biomarkers nor to a favorable cost-efficiency ratio in therapeutic decision making and this because of the methodological weakness and uncertainty that are identified in the selected studies. Practically, beyond the prognosis and predictive biomarkers validity, the clinical utility of a new biomarker for chemotherapy indication depends on its clinical added information with regard to validated biomarkers (HR, HER2 and Ki67) and to clinicopathological parameters. Since they are the sole validated biomarkers of the invasion process, uPA/PAI-1 could complete clinical information of other clinicopathological factors and consequently could confer an added clinical value. However, data concerning the impact of this information on chemotherapy clinical indication are lacking.Copyright © 2014. Published by Elsevier Masson SAS., IntroductionDans le cancer du sein, le développement des marqueurs biologiques pronostiques ou prédictifs a pour objectif de mieux identifier les patientes pour lesquelles un traitement par chimiothérapie pourrait être évité ou a contrario indiqué. Dans ce contexte, en 2009, l’Institut national du cancer (INCa), agence sanitaire et scientifique de l’État chargée de coordonner les actions de lutte contre le cancer, avait publié en partenariat avec la Société française de sénologie et de pathologie mammaire un rapport sur l’état des connaissances relatives aux biomarqueurs uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein. Ce rapport avait montré que seule la valeur pronostique d’uPA/PAI-1 atteignait le plus haut niveau de preuve (LOE I selon la grille de Hayes 1998). En 2012, devant la parution de nouvelles publications et la divergence des messages diffusés sur les signatures moléculaires, il a été décidé d’actualiser le rapport de 2009. Cet article présente les principales conclusions accompagnées de leurs niveaux de preuve.MéthodeLe processus de mise à jour s’est appuyé sur l’analyse des données publiées depuis la recherche bibliographique de 2009, complétée par l’avis d’un groupe de travail multidisciplinaire indépendant. Les niveaux de preuve employés sont ceux de la classification définie par Simon en 2009 (grille de Hayes 1998 après mise à jour) : LOE IA et LOE IB : niveau de preuve élevé ; LOE IIB and LOE IIC : niveau de preuve intermédiaire ; LOE IIIC and LOE IV-VD : niveau de preuve faible.ConclusionsChez les patientes sans envahissement ganglionnaire (pN0), uPA/PAI-1, marqueurs d’invasion, ont un niveau de preuve élevé (LOE IA selon Simon) pour la valeur pronostique de la survie sans récidive à 10 ans. Il reste à confirmer leur valeur prédictive de réponse aux anthracyclines. Pour Oncotype DX™ et MammaPrint®, les valeurs pronostique et prédictive n’ont pas atteint à ce jour le niveau de preuve LOE I. Ce travail confirme les niveaux de preuve précédemment établis dans le rapport de 2009. Par ailleurs, les données ne permettent pas de conclure à une valeur ajoutée de Oncotype DX™ et MammaPrint® par rapport aux outils existants. Les données médico-économiques ne permettent pas de statuer sur le rapport coût/efficacité des stratégies utilisant ces tests dans la décision thérapeutique compte tenu d’un niveau de qualité insuffisant pour la plupart des études et d’une forte incertitude mise en évidence par les quelques études bien menées. En pratique, au-delà des niveaux de preuve attribuables à la valeur pronostique et prédictive d’un biomarqueur, l’utilité clinique d’un nouveau marqueur dans l’aide à la prescription d’une chimiothérapie repose sur sa valeur ajoutée par rapport aux marqueurs validés (RH, HER2 et les marqueurs de prolifération comme Ki67) et aux critères anatomo-cliniques. Puisqu’ils sont les seuls marqueurs validés à témoigner du processus d’invasion, uPA/PAI-1 peuvent apporter une information complémentaire et donc avoir une valeur ajoutée par rapport aux marqueurs existants. Les données de la littérature manquent pour apprécier le poids de cette valeur ajoutée dans la décision de prescrire ou non une chimiothérapie.
- Published
- 2015
27. [Results of the Massive Open Online Course (MOOC) on cancer diagnosis and evaluation of its impact on the perception of the pathology specialty]
- Author
-
Charlotte, Gardair, Guilhem, Bousquet, Cédric, de Bazelaire, Jaqueline, Lehmann-Che, Patricia, de Cremoux, Jeanne, Tran Van Nhieu, Maxime, Battistella, Marie, Sockeel, Julien, Calvani, Michel, Peuchmaur, Thierry, Molina, Jocelyne, Gervais, Emilie, Moenaert, Yohann, Pottier, Laurent, Prévaut, Karima, Sekri, and Philippe, Bertheau
- Subjects
Adult ,Education, Distance ,Male ,Pathology, Clinical ,Attitude ,Neoplasms ,Humans ,Female ,Computer-Assisted Instruction - Abstract
The Massive Open Online Course (or MOOC) "Diagnostic Strategies Cancers", was hosted in autumn 2016 on the platform "France Université Numérique" and had two levels of learners: students in the field of health and biology and the general public. Of the 5285 learners in 81 different countries, 1237 (23%) were successfully certified. This MOOC was also integrated into the teaching program of medical students of Paris Diderot University and Paris 13 University. Using anonymous questionnaires before and after MOOC, it has been shown that pathology is less known than other medical specialties. Participation in this MOOC led to a marked improvement in participants' knowledge of the place and role of the pathologist in the diagnosis of cancers. Regarding the students who have followed the MOOC as part of their university course, their comments were very positive, but it is necessary to make substantial adjustments in the amounts and contents of the campus-based courses.
- Published
- 2017
28. Droplet Microfluidic and Magnetic Particles Platform for Cancer Typing
- Author
-
Davide, Ferraro, Jérôme, Champ, Bruno, Teste, M, Serra, Laurent, Malaquin, Stéphanie, Descroix, Patricia, de Cremoux, and Jean-Louis, Viovy
- Subjects
Reverse Transcriptase Polymerase Chain Reaction ,Neoplasms ,Microfluidics ,Biomarkers, Tumor ,Humans ,Reproducibility of Results ,Microfluidic Analytical Techniques ,Workflow - Abstract
Analyses of nucleic acids are routinely performed in hospital laboratories to detect gene alterations for cancer diagnosis and treatment decision. Among the different possible investigations, mRNA analysis provides information on abnormal levels of genes expression. Standard laboratory methods are still not adapted to the isolation and quantitation of low mRNA amounts and new techniques needs to be developed in particular for rare subsets analysis. By reducing the volume involved, time process, and the contamination risks, droplet microfluidics provide numerous advantages to perform analysis down to the single cell level.We report on a droplet microfluidic platform based on the manipulation of magnetic particles that allows the clinical analysis of tumor tissues. In particular, it allows the extraction of mRNA from the total-RNA sample, Reverse Transcription, and cDNA amplification, all in droplets.
- Published
- 2017
29. Droplet Microfluidic and Magnetic Particles Platform for Cancer Typing
- Author
-
Bruno Teste, Marco Serra, Laurent Malaquin, Jean-Louis Viovy, Jérôme Champ, Stéphanie Descroix, Davide Ferraro, Patricia de Cremoux, Physico-Chimie-Curie (PCC), Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC), Service de Génétique, Institut Curie-Hôpital, Université Paris Diderot - Paris 7 (UPD7), Centre de Recherches en Psychologie Cognition et Communication (CRPCC EA 1285), Université de Bretagne Sud (UBS)-Université de Brest (UBO)-MEN : EA1285-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Paris sciences et lettres (PSL), Équipe Ingénierie pour les sciences du vivant (LAAS-ELIA), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Magnetic tweezers ,Microfluidics ,02 engineering and technology ,Computational biology ,01 natural sciences ,Workflow ,Reverse Transcription (RT) ,Neoplasms ,Complementary DNA ,Genetics ,medicine ,Humans ,Droplet microfluidics ,Typing ,Droplet microfluidics PCR ,[SPI.NANO]Engineering Sciences [physics]/Micro and nanotechnologies/Microelectronics ,Molecular Biology ,Tumor ,Reverse Transcriptase Polymerase Chain Reaction ,Chemistry ,010401 analytical chemistry ,Reproducibility of Results ,Cancer ,Microfluidic Analytical Techniques ,021001 nanoscience & nanotechnology ,medicine.disease ,0104 chemical sciences ,PCR ,Nucleic acid ,Magnetic nanoparticles ,Reverse transcription (RT) ,Biomarkers, Tumor ,0210 nano-technology ,Biomarkers - Abstract
International audience; Analyses of nucleic acids are routinely performed in hospital laboratories to detect gene alterations for cancer diagnosis and treatment decision. Among the different possible investigations, mRNA analysis provides information on abnormal levels of genes expression. Standard laboratory methods are still not adapted to the isolation and quantitation of low mRNA amounts and new techniques needs to be developed in particular for rare subsets analysis. By reducing the volume involved, time process, and the contamination risks, droplet microfluidics provide numerous advantages to perform analysis down to the single cell level.We report on a droplet microfluidic platform based on the manipulation of magnetic particles that allows the clinical analysis of tumor tissues. In particular, it allows the extraction of mRNA from the total-RNA sample, Reverse Transcription, and cDNA amplification, all in droplets.
- Published
- 2017
30. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer
- Author
-
Michel Marty, Pascal Merlet, Elif Hindié, Patricia de Cremoux, Frédérique Berger, Anne-Sophie Hamy, M. Espie, Mathieu Hatt, Sylvie Giacchetti, Anne de Roquancourt, and David Groheux
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Triple Negative Breast Neoplasms ,Computed tomography ,Docetaxel ,Multimodal Imaging ,Disease-Free Survival ,Fluorodeoxyglucose positron emission tomography ,Breast cancer ,Fluorodeoxyglucose F18 ,Predictive Value of Tests ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Cyclophosphamide ,Triple-negative breast cancer ,Epirubicin ,Neoplasm Staging ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Immunohistochemistry ,Neoadjuvant Therapy ,Treatment Outcome ,Positron emission tomography ,Positron-Emission Tomography ,Biomarker (medicine) ,Female ,Taxoids ,Radiology ,Radiopharmaceuticals ,Tomography, X-Ray Computed ,business - Abstract
In patients with triple-negative breast cancer (TNBC), pathology complete response (pCR) to neoadjuvant chemotherapy (NAC) is associated with improved prognosis. This prospective study was designed and powered to investigate the ability of interim (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET/CT) to predict pathology outcomes to NAC early during treatment.Consecutive TNBC women underwent (18)FDG-PET/CT at baseline and after two courses of NAC. Maximum standardised uptake value (SUV(max)) in the primary tumour and lymph nodes at each examination and the evolution (ΔSUV(max)) between the two scans were measured. NAC was continued irrespective of PET results. Correlations between PET parameters and pathology response, and between PET parameters and event-free survival (EFS), were examined.Fifty patients without distant metastases were enroled. At completion of NAC, surgery showed pCR in 19 patients, while 31 had residual tumour. Mean follow-up was 30.3 months. Thirteen patients, all with residual tumour, experienced relapse. Of all assessed clinical, biological and PET parameters, ΔSUV(max) in the primary tumour was the most predictive of pathology results (p0.0001; Mann-Whitney-U test) and EFS (p=0.02; log rank test). A threshold of 42% decrease in SUV was identified because it offered the best accuracy in predicting EFS. There were 32 metabolic responders (⩾ 42% decrease in SUV(max)) and 18 non-responders. Within responders, the pCR rate was 59% and the 3-year EFS 77.5%. In non-responders, the pCR rate was 0% and the 3-year EFS 47.1%.Interim (18)FDG can early predict the inefficacy of NAC in TNBC patients. It shows promise as a potential contributory biomarker in these patients.
- Published
- 2014
31. A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1
- Author
-
Sarab Lizard, Fabienne Piard, Hélène Blons, Florence de Fraipont, Patricia de Cremoux, Jérôme Solassol, Ivan Bièche, Anne Cayre, Jean Mosser, Franck Morin, Caroline Domerg, Michèle Legrain, Jean-Luc Prétet, Pierre-Paul Bringuier, Marc G. Denis, Isabelle Rouquette, Anne-Claire Voegeli, Sylviane Olschwang, Nicolas Richard, Gérard Zalcman, Jacques Cadranel, Jean-Pierre Pignon, Michèle Beau-Faller, Isabelle Nanni-Metellus, Fabienne Escande, Patrick Saulnier, and Dorota Gajda
- Subjects
Oncology ,medicine.medical_specialty ,Cancer ,Nucleic acid amplification technique ,Biology ,medicine.disease_cause ,medicine.disease ,Bioinformatics ,3. Good health ,Pathology and Forensic Medicine ,Epidermal growth factor ,Internal medicine ,medicine ,biology.protein ,Molecular Medicine ,Adenocarcinoma ,KRAS ,Epidermal growth factor receptor ,Lung cancer ,Genotyping - Abstract
Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have limited use as first-line treatment for mutated EGFR metastatic non–small cell lung cancer. The French National Cancer Institute has installed molecular genetics platforms implementing EGFR and KRAS testing. However, there is considerable uncertainty as to which detection methods should be applied for routine diagnosis. This study aimed to compare the EGFR and KRAS genotyping methods developed by the IFCT/ERMETIC2 network platforms in two blind panels: 25 samples of serial dilutions of cell line DNA (20 centers) and 74 FFPE lung tumor samples (10 centers). The best threshold of mutation detection on cell lines was obtained using allele-specific amplification-based technologies. Nonamplifiable tissue samples were significantly less common when using alternative testing versus direct sequencing [15%; 95% confidence interval (CI), 14%–16% versus 40%; 95% CI, 39%–42%; P
- Published
- 2014
32. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
- Author
-
L. Roca, Jérôme Lemonnier, Anne-Laure Martin, Jean-Luc Canon, Véronique Diéras, Laurent Cany, Pierre Kerbrat, Henri Roché, Patricia de Cremoux, Christel Mesleard, Frédérique Penault-Llorca, Marc Spielmann, Stéphanie Chieze, and Emmanuelle Lappartient
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Heart Diseases ,Receptor, ErbB-2 ,Breast Neoplasms ,Pharmacology ,Antibodies, Monoclonal, Humanized ,Polymorphism, Single Nucleotide ,Asymptomatic ,Gastroenterology ,Disease-Free Survival ,Ventricular Dysfunction, Left ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,skin and connective tissue diseases ,Ejection fraction ,business.industry ,Receptors, IgG ,Middle Aged ,medicine.disease ,Oncology ,Docetaxel ,Chemotherapy, Adjuvant ,Fluorouracil ,Heart failure ,Toxicity ,Female ,medicine.symptom ,business ,Epirubicin ,medicine.drug - Abstract
The purpose of this study was to investigate, in the context of a prospective node-positive-breast cancer trial HER2 containing-regimen (UNICANCER-PACS 04 trial), the predictive value of HER2, FCGRIIA, and FCGRIIIA gene polymorphisms for cardiac toxicity and efficacy of trastuzumab. We analyzed HER2-I655V, FCGR2A-H131R, and FCGR3A-V158F single nucleotide polymorphisms in patients in adjuvant setting treated by six courses of either fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2) and cyclophosphamide 500 mg/m(2), or epirubicin 75 mg/m(2) and docetaxel 75 mg/m(2) every 3 weeks then randomly assigned, in case of HER2 overexpressing tumor, to either trastuzumab for 1 year or nothing. Left ventricular ejection fraction and clinical examination were monitored in each patient, seven times throughout the study to detect congestive heart failure or asymptomatic subclinical cardiac toxicity. All genotypes were analyzed in relation to cardiac toxicity, EFS, and OS. One hundred and thirty-two HER2-positive breast cancer patients were analyzed. The HER2-I655V genotype was significantly associated with cardiac toxicity (p = 0.025). The FCGR2A-131 H/H genotype was significantly correlated with a shorter EFS (p = 0.027). The FCGR3A-158 V/V genotype was not correlated with EFS nor OS. These results might be useful in making a treatment choice of HER2 blockers in adjuvant setting by with an increase in efficacy and decrease in toxicity.
- Published
- 2013
33. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer
- Author
-
Marc Espié, Sylvie Giacchetti, Marion Chapellier, Aurélie Scemama, Patricia de Cremoux, Mariana Varna, Raphael Richard, Cédric de Bazelaire, Isabelle Thomassin, and Eric de Kerviler
- Subjects
Adult ,medicine.medical_specialty ,Biopsy ,Breast surgery ,medicine.medical_treatment ,Breast Neoplasms ,Diffusion ,Breast cancer ,medicine ,Humans ,Effective diffusion coefficient ,Radiology, Nuclear Medicine and imaging ,Neoplasm Metastasis ,Neoadjuvant therapy ,Aged ,Retrospective Studies ,Chemotherapy ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,Interventional radiology ,General Medicine ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Neoadjuvant Therapy ,body regions ,Diffusion Magnetic Resonance Imaging ,Phenotype ,Treatment Outcome ,ROC Curve ,Female ,Radiology ,business ,Algorithms - Abstract
To evaluate the accuracy of the apparent diffusion coefficient (ADC) provided by diffusion-weighted imaging (DWI) in predicting the response to neoadjuvant chemotherapy (NACT) at baseline in patients according to their breast tumour phenotypes. This retrospective study was approved by our institutional review board. One hundred eighteen consecutive women with locally advanced breast cancer who had undergone NACT followed by breast surgery were included. DWI was performed at 1.5 T less than 2 weeks before NACT. We studied the correlation between pretreatment ADC and response in pathology after surgery according to immunohistochemical features and intrinsic subtypes (luminal A, luminal B, HER2-enriched, and triple-negative tumours). After surgery, the pathologist recognized 24 complete responders (CRps) and 94 non-complete responders (NCRps). No difference was identified between the pretreatment ADCs of the CRp and NCRp patients. There were differences in pretreatment ADCs among the luminal A (1.001 ± 0.143 × 10−3 mm2/s), luminal B (0.983 ± 0.150 × 10−3 mm2/s), HER2-enriched (1.132 ± 0.216 × 10−3 mm2/s), and triple-negative (1.168 ± 0.245 × 10−3 mm2/s; P = 0.0003) tumour subtypes. In triple-negative tumours, the pretreatment ADC was higher in NCRp (1.060 ± 0.143 × 10−3 mm2/s) than in CRp patients (1.227 ± 0.271 × 10−3 mm2/s; P = 0.047). Pretreatment ADC can predict the response of breast cancer to NACT if tumour subtypes are considered. Key Points • Apparent diffusion coefficient helps clinicians to assess patients with breast cancer. • Pretreatment ADC is related to tumour grade and hormone receptor status. • Pretreatment ADC is lower in luminal A and B than in triple-negative tumours. • Pretreatment ADC is higher in complete than in non-complete responders to neoadjuvant chemotherapy.
- Published
- 2013
34. Prevalence and Distribution of High-Risk Human Papillomavirus Genotypes in Invasive Carcinoma of the Uterine Cervix in Uruguay
- Author
-
Adela Sica, Nora Berois, Mabel Cedeira, Enrique Barrios, Patricia de Cremoux, Eduardo Osinaga, Xavier Sastre-Garau, Daniel Mazal, Benedicta Caserta, Tumor Immunology and Glycobiology / Glicobiología e Inmunobiología Tumoral [Montevideo], Institut Pasteur de Montevideo, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Département de Biopathologie, Institut Curie [Paris], Departamento de Anatomia Patologica y Citologia del Hospital de la Mujer, Centro Hospitalario Pereira Rossell, Departamento de Metodos Cuantitativos, Facultad de Medicina- Universidad de la República [Montevideo] (UCUR), and Departamento de inmunobiologia
- Subjects
[SDV]Life Sciences [q-bio] ,Uterine Cervical Neoplasms ,Gastroenterology ,law.invention ,0302 clinical medicine ,Risk Factors ,law ,Genotype ,Prevalence ,Papillomaviridae ,Polymerase chain reaction ,0303 health sciences ,High prevalence ,Invasive carcinoma ,Hpv types ,Obstetrics and Gynecology ,Human papillomavirus genotypes ,Middle Aged ,Prognosis ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,Adult ,medicine.medical_specialty ,Adenocarcinoma ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Invasive cervical cancer ,Humans ,Neoplasm Invasiveness ,Typing ,Human papillomavirus ,Retrospective Studies ,030304 developmental biology ,Gynecology ,business.industry ,Papillomavirus Infections ,Uterine Cervical Dysplasia ,Cross-Sectional Studies ,Uterine cervix ,DNA, Viral ,Uruguay ,Neoplasm Grading ,business ,Follow-Up Studies - Abstract
ObjectivesPersistent infection with specific genotypes of human papillomaviruses (HPVs) is the main cause of invasive cervical cancer (ICC). Only a few of the various HPV types account for most of the cases worldwide, and geographical differences in their distribution are evident. Data from locally prevalent genotypes are essential in view of introduction of HPV type-specific prophylactic vaccines.MethodsIn this work, we have investigated HPV type distribution in samples of ICC cases that occurred in Uruguayan women. DNA extracted from ICC treated in Centro Hospitalario Pereira Rossell of Montevideo between 1999 and 2007 were analyzed. Search and typing were performed by polymerase chain reaction using generic GP5+/GP6+ primers and specific primers for HPV types 16, 18, 33, and 45. Positive GP5+/GP6+ samples, which were negative for all 4 high-risk HPV-specific types screened were further analyzed by sequencing.ResultsHuman papillomavirus DNA sequences were found in 163 (92.6%) of 176 cases. The most prevalent genotypes were HPV16 (67.6%) and HPV18 (8.5%) followed by HPV45 (6.8%) and HPV33 (3.4%), as single or mixed infection. Other less frequent genotypes were HPV31, HPV35, HPV39, HPV51, HPV52, HPV58, HPV66, and HPV73. The viral type could not be determined (HPV X) in 1 case (0.6%) of the HPV DNA–positive cervical cancers and double infections were found in 1.7% of the cases. The higher percentage of most aggressive HPV (16/18/45) genotypes was detected in cases diagnosed at younger than 60 years old, whereas these genotypes were less frequent in older patients.ConclusionWe conclude that HPV types 16, 18, and 45 have a very high prevalence in ICC of Uruguayan women. Results provide evidence that 16 of 18 infections are more aggressive, but most cancers could be vaccine preventable.
- Published
- 2013
35. [Backstage of a massive open online course (MOOC) on cancer diagnosis]
- Author
-
Charlotte, Gardair, Guilhem, Bousquet, Jacqueline, Lehmann-Che, Cédric, de Bazelaire, Patricia, de Cremoux, Jeanne, Tran Van Nhieu, Marie, Sockeel, Maxime, Battistella, Julien, Calvani, Jocelyne, Gervais, Yohann, Pottier, Laurent, Prévaut, Karima, Sekri, and Philippe, Bertheau
- Subjects
Internet ,Neoplasms ,Pathology ,France ,Computer-Assisted Instruction - Abstract
Massive open online course (or MOOC) is a new online and open access teaching approach aimed at unlimited participation and providing interactions among students and teaching staff. These academic courses, often still free, lead to the delivery of a certificate of attendance and could soon also deliver a diploma. The MOOC "Stratégies diagnostiques des cancers" will be hosted in autumn 2016 on the platform "France Université Numérique" and will have two levels of learners: students in the field of health and biology and the general public. This MOOC will also be integrated into the teaching program of medical students of Paris Diderot University and Paris 13 University. The educational objective of this MOOC is to convey to all participants an overview of the diagnostic steps of cancers and of the various medical specialties involved in this diagnosis. The second week of the MOOC, entitled "tumor samples, macroscopic and microscopic analysis", presents the pathology specialty with the technical treatment of tissue or cell samples and the basic elements of the tissue section analysis to get a diagnosis of benign or malignant tumor. After this MOOC, it is planned to assess the impact of this new modality of teaching the pathology specialty or pathology, especially by the general public.
- Published
- 2016
36. [Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer]
- Author
-
Jean-Charles, Soria, Gérard, Bastian, Lina, Bolotine, Gilles, Calais, Jocelyn, Céraline, Patricia, de Cremoux, Marc, Espié, Lucie, Karayan-Tapon, Anne, Laprie, Jean-Jacques, Mazeron, Sylvie, Négrier, and Henri, Roché
- Subjects
Faculty, Medical ,Professional Competence ,Universities ,Organizational Case Studies ,Academies and Institutes ,Radiation Oncology ,Humans ,Organizational Objectives ,France ,Personnel Selection ,Research Personnel - Published
- 2016
37. [Ductal carcinoma in situ diagnosis: 3 French national guidelines]
- Author
-
Bruno, Cutuli, Christine, Tunon De Lara, Antoine, Arnaud, Philippe, Bertheau, Loïc, Boulanger, Véronique, Boute, Luc, Ceugnart, Marie-Pierre, Chauvet, Charles, Coutant, Patricia, De Cremoux, Alain, Fourquet, Christophe, Hennequin, Audrey, Lesieur, Anne, Lesur, Laurent, Lévy, Anne, Vincent-Salomon, Stéphanie, Besnard, and Chantal, Belorgey
- Subjects
Carcinoma, Intraductal, Noninfiltrating ,Carcinoma, Ductal, Breast ,Humans ,Breast Neoplasms ,Female - Abstract
Since the last guidelines published by the French National Cancer Institute (INCa) and the learning society "Société française de sénologie et de pathologie mammaire (SFSPM)" in 2009 about diagnosis and management of ductal carcinoma in situ, new data raised issues about overdiagnosis and its consequences, overtreatment. Therefore, an update was necessary, to provide healthcare professionals up-to-date guidelines and study therapeutic desescalation in particular.The clinical practice guidelines development process is based on systematic literature review and critical appraisal by a multidisciplinary experts workgroup. The recommendations are thus based on the best available evidence and experts agreement. Prior to publication, the guidelines are also reviewed by more than 100 independent practitioners in cancer care delivery.This article presents French guidelines about MRI and vacuum assisted breast biopsy indications for DCIS diagnosis and the management of low-grade DCIS.
- Published
- 2016
38. Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis
- Author
-
Laurent Malaquin, Davide Ferraro, Stéphanie Descroix, Jérôme Champ, Patricia de Cremoux, Jean-Louis Viovy, Marco Serra, Bruno Teste, MMBM Group, Institut Curie [Paris], Physico-Chimie-Curie (PCC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Curie [Paris]-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Équipe NanoBioSystèmes (LAAS-NBS), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Centre National de la Recherche Scientifique (CNRS)-Institut Curie [Paris]-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, HAL UPMC, Gestionnaire, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse Capitole (UT Capitole)
- Subjects
Magnetic tweezers ,Receptor, ErbB-2 ,Computer science ,Microfluidics ,Cell ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,02 engineering and technology ,Bioinformatics ,01 natural sciences ,Genetic analysis ,Article ,Cell Line ,Calibration ,Cell Line, Tumor ,Humans ,Neoplasms ,Magnetic Phenomena ,Multidisciplinary ,ErbB-2 ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology ,medicine ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,[SDV.IB] Life Sciences [q-bio]/Bioengineering ,Her2 expression ,Tumor ,010401 analytical chemistry ,Robustness (evolution) ,021001 nanoscience & nanotechnology ,Precision medicine ,0104 chemical sciences ,3. Good health ,medicine.anatomical_structure ,Cell culture ,[SDV.IB]Life Sciences [q-bio]/Bioengineering ,RNA extraction ,0210 nano-technology ,Biomedical engineering ,Receptor - Abstract
The development of precision medicine, together with the multiplication of targeted therapies and associated molecular biomarkers, call for major progress in genetic analysis methods, allowing increased multiplexing and the implementation of more complex decision trees, without cost increase or loss of robustness. We present a platform combining droplet microfluidics and magnetic tweezers, performing RNA purification, reverse transcription and amplification in a fully automated and programmable way, in droplets of 250nL directly sampled from a microtiter-plate. This platform decreases sample consumption about 100 fold as compared to current robotized platforms and it reduces human manipulations and contamination risk. The platform’s performance was first evaluated on cell lines, showing robust operation on RNA quantities corresponding to less than one cell and then clinically validated with a cohort of 21 breast cancer samples, for the determination of their HER2 expression status, in a blind comparison with an established routine clinical analysis.
- Published
- 2016
39. Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer
- Author
-
Véronique Scott, O Tembo, Jacqueline Lehmann-Che, Ivan Bièche, Michel Marty, Patricia de Cremoux, Bernard Asselain, Frédérique Spyratos, and Fabien Valet
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Microarray ,business.industry ,Large dynamic range ,medicine.disease ,Standard technique ,Continuous variable ,Protein content ,Breast cancer ,Internal medicine ,medicine ,DNA microarray ,business ,Semi quantitative - Abstract
In addition to their major interest in refining disease classifications and improving diagnostic and prognostic accuracy by means of molecular signatures, microarrays have been proposed in breast cancer as an alternative to routine immunohistochemistry (IHC) determination of biomarkers such as estrogen and progesterone receptors (ER, PR) and HER2, that are crucial for treatment decisions in breast cancer. IHC is currently the standard technique for determination of ER, PR, and HER2 status, with additional in situ hybridization assays to clarify equivocal HER2 IHC results. Despite its long-term use and efforts to achieve interlaboratory standardization and quality control programs, marked variability in the determination of these variables has been reported between pathology laboratories with relatively high false-positive (for HER2) and falsenegative rates (for ER and PR) [1]. The historical ligandbinding assay reported ER and PR protein content on a continuous scale with a large dynamic range. ER and PR IHC data are now used as a dichotomous variable, and information has been lost compared to the results obtained with continuous variables (high ER values correlated with better response to hormone therapy) [2, 3]. Semi quantitative IHC approaches have been proposed, but implementation of such systems in different laboratories gives results that may differ from one laboratory to another Electronic supplementary material The online version of this article (doi:10.1007/s10549-012-2042-4) contains supplementary material, which is available to authorized users.
- Published
- 2012
40. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- Author
-
Frédérique Spyratos, Margaret Haugh, Alain Fourquet, Anne Gompel, Hubert Crouet, Bruno Poulet, Caroline Egele, Etienne Brain, Marc Spielmann, Jocelyne Jacquemier, Nicole Tubiana-Mathieu, Pierre-Marie Martin, Patricia de Cremoux, Brigitte Sigal-Zafrani, Frédérique Penault-Llorca, Nicolas Rouyer, Marie-Pierre Chenard, Jean-Pierre Lefranc, Elisabeth Luporsi, Laurent Arnould, Fabrice Andre, Krishna B. Clough, Carole Mathelin, Daniel Serin, and Jean-Pierre Bellocq
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Prognostic factor ,Multivariate analysis ,MEDLINE ,Breast Neoplasms ,Review ,law.invention ,Breast cancer ,Randomized controlled trial ,law ,Internal medicine ,Biomarkers, Tumor ,Medicine & Public Health ,medicine ,Humans ,Neoplasm Invasiveness ,Randomized Controlled Trials as Topic ,biology ,business.industry ,Carcinoma ,Evidence-based medicine ,Prognosis ,medicine.disease ,Surgery ,Ki-67 Antigen ,Treatment Outcome ,Ki-67 ,biology.protein ,Biomarker (medicine) ,Female ,Predictive factor ,business - Abstract
Clinicians can use biomarkers to guide therapeutic decisions in estrogen receptor positive (ER+) breast cancer. One such biomarker is cellular proliferation as evaluated by Ki-67. This biomarker has been extensively studied and is easily assayed by histopathologists but it is not currently accepted as a standard. This review focuses on its prognostic and predictive value, and on methodological considerations for its measurement and the cut-points used for treatment decision. Data describing study design, patients’ characteristics, methods used and results were extracted from papers published between January 1990 and July 2010. In addition, the studies were assessed using the REMARK tool. Ki-67 is an independent prognostic factor for disease-free survival (HR 1.05–1.72) in multivariate analyses studies using samples from randomized clinical trials with secondary central analysis of the biomarker. The level of evidence (LOE) was judged to be I-B with the recently revised definition of Simon. However, standardization of the techniques and scoring methods are needed for the integration of this biomarker in everyday practice. Ki-67 was not found to be predictive for long-term follow-up after chemotherapy. Nevertheless, high KI-67 was found to be associated with immediate pathological complete response in the neoadjuvant setting, with an LOE of II-B. The REMARK score improved over time (with a range of 6–13/20 vs. 10–18/20, before and after 2005, respectively). KI-67 could be considered as a prognostic biomarker for therapeutic decision. It is assessed with a simple assay that could be standardized. However, international guidelines are needed for routine clinical use.
- Published
- 2011
41. Hormonothérapie des cancers du sein
- Author
-
Patricia de Cremoux
- Subjects
Cancer Research ,biology ,Fulvestrant ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,Estrogen receptor ,Hematology ,General Medicine ,medicine.disease ,Breast cancer ,Oncology ,Estrogen ,Selective estrogen receptor modulator ,Cancer research ,medicine ,biology.protein ,Radiology, Nuclear Medicine and imaging ,Hormone therapy ,Aromatase ,Receptor ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
The nuclear estrogen receptors (ER) are the major targets for endocrine treatment of hormone-dependent breast cancers. Hormone therapy blocked endogenous estrogen activation of ER, either by competitive inhibition of endogenous estrogens (selective estrogen receptor modulators – SERM or selective estrogen receptor down regulators – SERD) or by inhibition of estrogen synthesis (aromatase inhibitors) from adrenal androgens in post-menopausal women. The efficacy of these treatments has been shown on large series of breast cancer patients. However de novo or acquired resistance to treatment occurs. The better knowledge of the mechanism of action of such treatment may help to better understand them, and also for the determinism of adverse side effects of the different class of molecules.
- Published
- 2011
42. Gastric metastasis of breast cancer: A single centre retrospective study
- Author
-
Fabien Reyal, Pascale Mariani, B. Baranger, M.M. Almubarak, Simon P. Bennett, Marick Laé, Jean-Yves Pierga, Wulfran Cacheux, Patricia de Cremoux, Rémy Salmon, and Marie-Christine Falcou
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Receptor, ErbB-2 ,Vomiting ,Breast Neoplasms ,Kaplan-Meier Estimate ,Gastroenterology ,Metastasis ,Breast cancer ,Stomach Neoplasms ,Median follow-up ,Internal medicine ,Weight Loss ,Carcinoma ,Humans ,Medicine ,Survival rate ,Peritoneal Neoplasms ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hepatology ,business.industry ,Stomach ,Nausea ,Middle Aged ,medicine.disease ,Abdominal Pain ,Carcinoma, Lobular ,medicine.anatomical_structure ,Receptors, Estrogen ,Invasive lobular carcinoma ,Female ,Receptors, Progesterone ,business ,Breast carcinoma - Abstract
Background Digestive metastasis of breast cancer are rare but when they do occur the stomach is one of the commoner sites. Aim To describe the clinical, endoscopic, pathological features and treatment. Methods 35 cases of gastric metastasis were identified retrospectively between 1980 and 2008. Results The location of the gastric metastasis was fundus (n = 15, 43%), antrum (n = 15, 43%) or both (n = 5, 14%). The histological subtype of primary breast cancer was invasive lobular carcinoma in 34 patients (97%). Hormonal receptors were positive in 19 out of 24 cases (79%), two out of 22 analysed were HER2 positive (9%). There were 16 (46%) patients with peritoneal carcinosis. The treatment was chemotherapy (n = 13, 37%), hormonotherapy (n = 2, 6%) or both (n = 13, 37%). The 2-year survival rate after gastric metastasis diagnosis was 53% with a median follow up of 31 months [7–84 months]. Conclusion Ninety-seven percent of gastric metastasis from breast cancers are derived from invasive lobular carcinoma. Seventy-nine percent of these are HER+ and comparison with the original histopathological slides of primary breast carcinoma should be performed to differentiate gastric metastasis from primary gastric carcinoma. Peritoneal carcinomatosis accompanied gastric metastasis in almost half the cases in this series and treatment was generally chemotherapy.
- Published
- 2011
43. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
- Author
-
Jean-Yves Pierga, Marie-Christine Etienne-Grimaldi, Patricia Formento, Mireille Francoual, Gérard Milano, Florence Dalenc, A. Degeorges, Rémi Delva, Xavier Pivot, Marc Espié, Corinne Veyret, Patricia de Cremoux, Jean-Louis Formento, and Magali Piutti
- Subjects
Pharmacology ,Oncology ,medicine.medical_specialty ,Pathology ,genetic structures ,Bevacizumab ,business.industry ,Cancer ,medicine.disease ,Metastatic breast cancer ,eye diseases ,Metastasis ,Breast cancer ,Pharmacodynamics ,Internal medicine ,medicine ,Pharmacology (medical) ,sense organs ,Breast disease ,skin and connective tissue diseases ,business ,Prospective cohort study ,medicine.drug - Abstract
AIMS To test prospectively the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-chemotherapy in breast cancer patients.
- Published
- 2011
44. Prognostic factors for local recurrence following breast-conserving treatment in young women
- Author
-
Fabien Reyal, Youlia M. Kirova, Marc A. Bollet, Alain Fourquet, and Patricia de Cremoux
- Subjects
Oncology ,Prognostic factor ,medicine.medical_specialty ,Breast Neoplasms ,Mastectomy, Segmental ,Therapeutic approach ,Breast cancer ,Older patients ,Internal medicine ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Pharmacology (medical) ,business.industry ,Incidence (epidemiology) ,Age Factors ,Prognosis ,medicine.disease ,Surgery ,Young age ,Female ,Neoplasm Recurrence, Local ,business ,Rare disease - Abstract
Breast cancer is a rare disease in young women. Its incidence has remained remarkably constant over the last decades, contrary to what has happened in older patients. Age is a major prognostic factor for local control after breast-conserving treatments, which does not seem to be entirely explained by the poor prognostic features that are more commonly associated with breast cancers in young women. A better knowledge of the prognostic factors for local control, and, whenever possible, those pertaining specifically to the young age group, is key, not only to better select the patients who would benefit the most from a breast-conserving approach but also to enhance the local control when this option has been elected. These prognostic factors can be related to the patient, the tumor and the treatment they receive. Finally, we will present a perspective of what the future could hold, both in terms of the selection of the patients and of a more customized therapeutic approach.
- Published
- 2010
45. Ocular adnexal lymphoma and Helicobacter pylori gastric infection
- Author
-
Claire Mathiot, J. Girodet, Nicole Brousse, Jean-Luc Beretti, Frédéric Mal, Corine Plancher, Bernard Asselain, Pierre Validire, Agnès Ferroni, Livia Lumbroso-Le Rouic, Kheira Beldjord, Patricia Validire, Patricia de Cremoux, Rémi Dendale, Anne Vincent-Salomon, E Macintyre, Marc Lecuit, Didier Decaudin, Olivier Hermine, Institut Curie [Paris], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Institut Mutualiste de Montsouris (IMM), Microorganismes et Barrières de l'Hôte (Equipe avenir), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, and Equipe avenir Microorganismes et Barrières de l'Hôte
- Subjects
Male ,Pathology ,MESH: Eye Neoplasms ,Gastroenterology ,Cohort Studies ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,MESH: Lymphoma, B-Cell, Marginal Zone ,Stomach cancer ,MESH: Cohort Studies ,[SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology ,MESH: Aged ,MESH: Middle Aged ,Hematology ,biology ,Stomach ,digestive, oral, and skin physiology ,Middle Aged ,3. Good health ,medicine.anatomical_structure ,Gastritis ,030220 oncology & carcinogenesis ,Medicine ,Female ,MESH: Gastritis ,medicine.symptom ,Adult ,medicine.medical_specialty ,Helicobacter Infections ,03 medical and health sciences ,Ocular Adnexal Lymphoma ,Internal medicine ,medicine ,Humans ,Aged ,Gastric Infection ,MESH: Humans ,Helicobacter pylori ,business.industry ,Eye Neoplasms ,MESH: Helicobacter Infections ,MESH: Adult ,Lymphoma, B-Cell, Marginal Zone ,biology.organism_classification ,medicine.disease ,digestive system diseases ,MESH: Male ,Lymphoma ,030221 ophthalmology & optometry ,MESH: Helicobacter pylori ,business ,MESH: Female - Abstract
There is a causal association between Helicobacter pylori (Hp) gastric infection and the development of gastric MALT lymphoma. In contrast, the link between Hp gastric infection and the development of extragastric lymphoma has not been thoroughly investigated. We, therefore, studied the prevalence of gastric Hp infection at initial diagnosis of ophthalmologic and nonophthalmologic extragastric lymphoma patients. Three cohorts of patients were studied: a first one of 83 patients with OAL, a second one of 101 patients with extraophthalmologic extragastric lymphoma, and a third one of 156 control individuals (control) without malignant lymphoma. Gastric Hp infection was investigated by histopathological analysis and Hp-specific PCR assay on gastric biopsy tissue samples. We found gastric Hp infection in 37 OAL patients (45%), in 25 extraophthalmologic extragastric lymphoma cases (25%), and in 18 controls individuals (12%) (P < 0.0001 OAL/C and P < 0.01 OAL/extra-OAL cases). Gastritis was found in 51% and 9% of Hp-positive and Hp-negative lymphoma patients, respectively (P < 10−4). Gastric Hp infection only correlated with MALT/LPL lymphoma (P = 0.03). There is a significant association between gastric Hp infection and MALT/LPL OAL. This suggests a novel mechanism of indirect infection-associated lymphomagenesis whereby chronic local antigen stimulation would lead to the emergence of ectopic B-cell lymphoma. © 2010 Wiley-Liss, Inc. Am. J. Hematol.
- Published
- 2010
46. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma
- Author
-
Philippe Hupé, Jérôme Couturier, Patricia de Cremoux, Martine Peter, Paul Cottu, Nicolas Stransky, Emmanuel Barillot, François Radvanyi, and Xavier Sastre-Garau
- Subjects
Genetics ,Cervical cancer ,Locus (genetics) ,Biology ,medicine.disease_cause ,medicine.disease ,Genome ,Gene dosage ,Pathology and Forensic Medicine ,medicine.anatomical_structure ,medicine ,Carcinoma ,Carcinogenesis ,Cervix ,Gene - Abstract
To investigate whether integration of HPV DNA in cervical carcinoma is responsible for structural alterations of the host genome at the insertion site, a series of 34 primary cervical carcinomas and eight cervical cancer-derived cell lines were analysed. DNA copy number profiles were assessed using the Affymetrix GeneChip Human Mapping 250K Sty array. HPV 16, 18 or 45 integration sites were determined using the DIPS-PCR technique. The genome status at integration sites was classified as follows: no change, amplification, transition normal/gain, normal/loss or gain/LOH. A single HPV integration site was found in 34 cases; two sites were found in seven cases; and three sites in one case (51 sites). Comparison between integration sites and DNA copy number profiles showed that the genome status was altered at 17/51 (33%) integration sites, corresponding to 16/42 cases (38%). Alterations detected were amplification in nine cases, transition normal/loss in four cases, normal/gain in three cases, and gain/LOH in one case. A highly significant association was found between genomic rearrangement and integration of HPV DNA (p < 10(-10)). Activation of the replication origin located in viral integrated sequences in a cell line derived from one of the primary cervical carcinomas induced an increase of the amplification level of both viral and cellular DNA sequences flanking the integration locus. This mechanism may be implicated in the triggering of genome amplification at the HPV integration site in cervical carcinoma. Structural alterations of the host genome are frequently observed at the integration site of HPV DNA in cervical cancer and may act in oncogenesis.
- Published
- 2010
47. Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts
- Author
-
Jean-Gabriel Judde, Pierre Laurent-Puig, Catherine Daniel, Fariba Nemati, Marie-France Poupon, Gonzague de Pinieux, Rui Bras-Gonçalves, Patricia de Cremoux, Vincent Bordier, Jean-Jacques Fontaine, Alain Livartowski, Didier Decaudin, and A. Chapelier
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Cell ,Mice, Nude ,Docetaxel ,Drug resistance ,Vinorelbine ,Mice ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,Lung cancer ,neoplasms ,Aged ,Pharmacology ,Cisplatin ,Chemotherapy ,business.industry ,Middle Aged ,Genes, p53 ,medicine.disease ,Xenograft Model Antitumor Assays ,Gemcitabine ,respiratory tract diseases ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Drug Resistance, Neoplasm ,Female ,Taxoids ,business ,medicine.drug - Abstract
The success of treatment of advanced non-small-cell lung cancer (NSCLC) remains very poor. The aim of this study was, on a series of NSCLC xenografts, to compare the efficacy of standard cisplatin-based or docetaxel-based chemotherapy. Seven human xenografts were obtained from six patients (two xenografts were derived from primary or metastatic tumors of the same patient). Three xenografts were adenocarcinomas and four were squamous cell carcinomas. All xenografts reproduced the same histology as that of the patient's original tumor. Docetaxel, administered as single-agent chemotherapy, induced a significant response in five of the seven NSCLC xenografts (71%), without significant increase after combination with cisplatin, vinorelbine, or gemcitabine. Relative expression of genes putatively involved in drug response was also studied in all xenografts and did not explain the variability of drug sensitivity. In conclusion, this panel of human NSCLC xenografts reliably reproduces the data obtained in patient tumors and the relative sensitivity to docetaxel reported in NSCLC patients.
- Published
- 2009
48. Variable association between Chlamydophila psittaci infection and ocular adnexal lymphomas: methodological biases or true geographical variations?
- Author
-
Didier Decaudin, Andrés J.M. Ferreri, Patricia de Cremoux, Claudio Doglioni, Maurilio Ponzoni, Anne Vincent-Salomon, Livia Lumbroso-Le Rouic, Riccardo Dolcetti, Marie Christine Escande, and Rémi Dendale
- Subjects
Cancer Research ,medicine.medical_specialty ,Biology ,urologic and male genital diseases ,Psittacosis ,Bias ,Ocular Adnexal Lymphoma ,Seroepidemiologic Studies ,Epidemiology ,medicine ,Humans ,Seroprevalence ,Pharmacology (medical) ,Pharmacology ,Chlamydia psittaci ,Chlamydophila ,Geography ,Eye Neoplasms ,MALT lymphoma ,Lymphoma, B-Cell, Marginal Zone ,bacterial infections and mycoses ,biology.organism_classification ,medicine.disease ,eye diseases ,female genital diseases and pregnancy complications ,Chlamydophila psittaci ,Oncology ,Immunology - Abstract
Since the first publication in 2004, a large number of reports have raised the question of an association between ocular adnexal lymphoma and Chlamydia psittaci. The results of this scientific debate, however, remain controversial. The primary objective of this paper was therefore to raise important questions concerning the interpretation of the different and heterogeneous data on the association between Chlamydophila psittaci and ocular adnexal lymphoma, namely the impact of the methodology used and the epidemiological variability of seroprevalence of C. psittaci antibodies. This paper also provides some methodological suggestions for future studies in the field of chlamydia-lymphoma associations.
- Published
- 2008
49. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease
- Author
-
Patricia de Cremoux, Daniel W. Rosenberg, Jérôme Bertherat, Lionnel Groussin, Catherine Brémont-Weil, Marie-Laure Raffin-Sanson, Carine Tran-Perennou, Xavier Bertagna, Frédérique Tissier, and Jacques Goussard
- Subjects
Adrenal Cortex Diseases ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Steroid ,Aromatase ,Cytosol ,Endocrinology ,Internal medicine ,Progesterone receptor ,medicine ,Estrogen Receptor beta ,Humans ,RNA, Messenger ,Child ,Receptor ,Aged ,Aged, 80 and over ,Regulation of gene expression ,biology ,Adrenal cortex ,Estrogen Receptor alpha ,Middle Aged ,Adrenal Cortex Neoplasms ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Oncology ,Adrenocortical Adenoma ,Adrenal Cortex ,biology.protein ,Immunohistochemistry ,Female ,Receptors, Progesterone ,Primary pigmented nodular adrenocortical disease - Abstract
Adrenal tumors occur more frequently in women and are the leading cause of Cushing's syndrome during pregnancy. We aimed to evaluate the potential role of sex steroids in the susceptibility of women to adrenocortical tumors. We evaluated the presence of the progesterone receptor (PR), estradiol receptors (ERs), and aromatase in 5 patients with primary pigmented nodular adrenal disease (PPNAD), 15 adrenocortical adenomas (ACAs) and adjacent normal tissues, 12 adrenocortical carcinomas (ACCs), and 3 normal adrenal glands (NA). The expression of PR and ERalpha was evaluated by enzyme immunoassays, real-time RT-PCR, immunohistochemistry, and cytosol-based ligand-binding assays. ERbeta and aromatase levels were evaluated by real-time RT-PCR. ERalpha concentrations were low in NA, in adrenal tissues adjacent to ACA (51+/-33), in ACC (53+/-78), and lower in ACA (11+/-11 fmol/mg DNA). Conversely, PR concentrations were high in NA and adrenal tissues adjacent to ACA, at 307+/-216 fmol/mg DNA, and were even higher in tumors - 726+/-706 fmol/mg DNA in ACA and 1154+/-1586 fmol/mg DNA in ACC - and in isolated PPNAD nodules. Binding study results in four tumors were compatible with binding to a steroid receptor. In patients with PPNAD, a strong positive immunohistochemical signal was associated with the sole isolated nodular regions. ERbeta transcript levels were very high in all samples except those for two ACCs, whereas aromatase levels were low. PR and ERbeta are clearly present in normal adrenal glands and adrenal tumors. Further studies may shed light on the possible pathogenic role of these receptors in adrenal proliferation.
- Published
- 2008
50. Anomalies moléculaires des cancers : Ciblage thérapeutique
- Author
-
Karen Leroy, Patricia de Cremoux, Karen Leroy, and Patricia de Cremoux
- Subjects
- Cancer--Treatment, Cancer--Molecular aspects
- Abstract
L'augmentation spectaculaire des connaissances dans le domaine de la biologie des cellules tumorales et l'identification des anomalies génétiques, ouvrent des perspectives enthousiasmantes pour le développement de nouveaux traitements, plus'personnalisés', plus efficaces et moins toxiques. De nouvelles thérapeutiques ciblant ces altérations moléculaires tumorales voient alors le jour. Vu leur efficacité dans le traitement des leucémies myéloïdes chroniques et des tumeurs stomales gastro-intestinales, cette innovation devient pratique courante pour plusieurs autres cancers. A travers 18 chapitres, cet ouvrage, clair et illustré, propose une vue d'ensemble sur ces anomalies et les options thérapeutiques : Toutes les connaissances à jour et les bases fondamentales : les voies de signalisation altérées dans les processus tumoraux, les altérations du génome, les nouvelles techniques de séquençage. Un chapitre spécialisé par type de cancer écrit par les meilleurs spécialistes de chaque domaine : sarcome, cancer bronchique, colorectal, sein, rein, thyroïde, vessie, mélanome, ovaire... Pour chacun : La description complète des cibles (caractéristiques, biomarqueurs, thérapies ciblant la molécule) La place des thérapeutiques ciblées dans le domaine Les perspectives attendues
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.